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OBJECTIVES: Treatment-to-Goal analyses are com-
monly used to predict population blood pressure (BP)
control rates for antihypertensive agents based on mean
BP lowering. However, control rates are frequently inac-
curate because variability in BP reduction and baseline
BPs are not considered. This study presents a new
methodology that improves on population BP control
estimates. METHODS: Untreated hypertensive patients
(n = 2483) from the Third National Health and Nutri-
tion Examination Survey formed the test-sample. Monte
Carlo simulation trials (MCST) of 500 patient-level BP
reductions were generated from 3 underlying distribu-
tions: normal, lognormal, and beta. BP control, deﬁned
as SBP < 140 and DBP < 90mmHg, was estimated by 3
methods: parametric- MCST-based means and variances
were used to generate BP lowering data, assuming a
normal distribution, and were subtracted from test-
sample baseline BPs; point-estimate- mean BP reductions
from MCST were directly subtracted from baseline BPs;
bootstrapping- MCST BP reductions were bootstrapped
with replacement and applied to the test-sample. Para-
metric and point-estimate results were compared to more
comprehensive bootstrapping estimates for each simula-
tion trial. We also investigated the relative performance
of each method in the subgroup patients at three hyper-
tension stages deﬁned in the JNC VI guideline. RESULTS:
We assumed a mean (+-SD) BP lowering of 20(12) and
14(7) mmHg systolic and diastolic. Parametric, boot-
strapping, and point-estimate methods projected BP
control rates of 66.9, 67.3, and 75.5%, respectively. The
Point-estimate method frequently projected inaccurate
control rates while the parametric results were shown
consistent with the bootstrap method under a wide range
of model conditions. CONCLUSIONS: Regardless of 
the underlying data distribution, parametric method pro-
vides more accurate control rates than point-estimate.
Since patient-level BP reduction trial data are frequently
unavailable to researchers, this parametric method can 
be used to generate more accurate treatment to goal
analyses. This methodology can be extended to other
therapeutic areas to estimate treatment effectiveness.
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OBJECTIVE: To combine the results of the four pub-
lished clinical trials comparing rosuvastatin with either
atorvastatin, pravastatin or simvastatin by meta-analysis
to quantify the magnitude of difference in the percentage
of patients failing to achieve the European Atherosclero-
sis Society (EAS) target for LDL-C of <3mmol/L at 12
weeks. Patients included in the clinical trials had an initial
LDL-C ≥160 (4.1mmol/L) and <250mg/dL (6.5mmol/L).
METHODS: Meta-analysis of patients failing to achieve
the EAS target at 12 weeks calculated by intention-to-
treat (ITT) analysis. ITT was deﬁned as, “patients being
analysed in the treatment arm that they entered at 
randomisation, regardless of whether they dropped-out,
received the incorrect treatment or withdrew before com-
pletion of the trial”. RESULTS: Rosuvastatin 10mg is
more effective at lowering LDL-C to the EAS target than
atorvastatin 10mg, pravastatin 20mg and simvastatin 20
mg at 12 weeks. There is an increase in the relative risk
of failing to achieve the EAS target for LDL-C with ator-
vastatin 10mg (RR 2.31; 95%CI: 1.76 to 3.04), pra-
vastatin 20mg (RR 3.91; 95%CI: 3.05 to 5.03) and
simvastatin 20mg (RR 2.41; 95%CI: 1.83 to 3.16), com-
pared to rosuvastatin 10mg. A chi-squared test was
carried out to investigate possible heterogeneity in each
of the comparisons. Signiﬁcant heterogeneity was not
detected in any of the comparisons made. CONCLU-
SIONS: Compared to rosuvastatin 10mg, there is a sig-
niﬁcant increase in the risk of failing to achieve the EAS
target for LDL-C with atorvastatin 10mg, pravastatin 
20mg and simvastatin 20mg at 12 weeks.
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OBJECTIVES: The reported incidence of bleeding asso-
ciated with oral anticoagulation therapy varies widely.
The study objectives were to identify good quality evi-
dence about risk of bleeding and to investigate the impact
of study heterogeneity on outcomes. METHODS: A
search was made of MEDLINE and EMBASE for ran-
domised controlled trials and inception cohort studies
between January 1990 and March 2002. Selection crite-
ria were: anticoagulation monitored by INR, percent-
age time within range stated, and criteria for deﬁning a
major bleed stated. The sensitivity of diagnostic criteria
for bleeding events was investigated by assembling a six-
month cross sectional retrospective cohort of anticoagu-
lated patients. Outcome events in this cohort were then
assessed against the criteria for “major bleeds” proposed
by each reviewed study. RESULTS: Twelve studies were
identiﬁed that met the selection criteria. Signiﬁcant vari-
ation was seen in the major bleed rates across the studies
